Hims & Hers Health said Wednesday it will offer five formulations of peptides and longevity treatments compounded in the U.S. as the first rollout of its Peptides+ platform, none of which are approved by regulators. In the same announcement the company acknowledged it has more to learn about how best to use the peptides and how effective they are.
The initial lineup includes compounded sermorelin, a peptide that stimulates growth-hormone release and is marketed for recovery, body composition and anti-aging, plus glutathione, NAD+, vitamin B-12 and L-carnitine. BPC-157 and TB-500 are planned additions, and CNBC notes most of the research on both has been done in animals rather than humans.
Why this is legal now
The launch follows an October policy from the Health and Human Services Department saying the FDA will not take enforcement action against licensed pharmacies, federal facilities or physicians compounding six unapproved peptides while formal rules are reviewed. That is not approval, and the peptides are still not on the FDA's official list of ingredients compounding pharmacies may use.
HHS Secretary Robert F. Kennedy Jr. has called himself a "big fan" of the treatments and has described using BPC-157 for a muscle injury. The policy reverses a 2023 FDA restriction imposed over safety, impurity and immune-reaction concerns.
Where the evidence stops
A 2026 systematic review screening 113 studies, human and rodent, found zero eligible clinical outcome trials showing that IV or intramuscular NAD+ improves anti-aging, energy or wellness endpoints in humans. A review of 37 L-carnitine trials found participants lost about 2.7 pounds on average, though that does not show a compounded injection behaves the same way.
Glutathione is thinner still. The FDA said in August it had received reports of at least 30 patients who experienced adverse events after receiving compounded IV glutathione, traced to one wholesale distributor supplying dietary supplement grade material.
The dosing question nobody answers
"The dosing for these products really has not been established," UC Davis professor Paul Knoepfler told CNBC, warning that excess synthetic peptide could trigger immune responses. Tufts chemistry professor Joshua Kritzer said online-only supervision "is not enough" for an unapproved prescription product.
Bottom line
Demand is clearly there: more than 10,000 people joined the early access list within 15 days, a company spokesperson said. What is not there is the trial data, and Hims' own chief medical officer is the one saying so.
Comments (0)
Discussion happens on Reddit.
Go to r/PeptideNewsroomQuestions and corrections go to r/PeptideNewsroom.